Background:
The SLE-key ® test was developed by ImmunArray and was validated to rule out SLE with 94% sensitivity, 75% specificity and a negative predictive value (NPV) of 93% 1 . We reported earlier that the SLE-key ® RuleOut test could aid in the diagnosis and disposition of a cohort of 55 patients in our clinical practice 2 . Objectives: We have now expanded this cohort and report here the usefulness of the SLE-key ® test in aiding the management of a cohort of challenging and suspected SLE patients in a large clinical practice. Methods: In patients referred to the Rheumatology and Immunotherapy Center, in Franklin, WI, results from the SLE-key ® RuleOut test were included as part of the clinical evaluation. Serum samples were collected from individual subjects with informed consent and tested at VERACIS (Richmond, VA), using the SLE-Key ® iCHIP ®1 . Results: We reviewed the diagnoses and clinical disposition of patients both before and after SLE-key ® testing. In particular, we looked at the ability of the SLE-key ® test to enhance our ability to reach a definitive diagnosis across the full cohort of patients, at the disposition of patients who were referred with a suspicion of SLE as part of the differential diagnosis, at the impact of SLE-key ® testing on the diagnosis of the subset of patients who presented with minimal symptoms, and at the group of patients who had been referred following an ANA test. Results are summarized in Table 1 . In the cases where SLE was ruled out, patients were treated for a variety of disorders including fibromyalgia, joint pain, MCTD, Sjogren's disease and others. 
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Background: Infection is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). The spectrum of infectious agents in SLE patients varies significantly among different ethnic groups. The national surveillance study from the China showed that Gram-negative bacteria (GNB) was the most the common bacterial infection in China, while Gram-positive bacteria (GPB) was predominant in European countries. Objectives: To identify the spectrum and drug resistant pattern of infection caused by GNB in patients hospitalized with SLE.
Methods:
The clinical and microbiological data from hospitalized SLE patients with bacterial infection between June 2005 and June 2015 was collected and then analyzed retrospectively. Results: Two hundred and sixty-eight episodes of bacteria had been identified from 3815 hospitalized patients. In terms of isolated microorganisms, gramnegative bacteria (GNB) were predominant over gram-positive bacteria (GPB) (178 isolates vs. 90 isolates). In the GNB, Escherichia coli (66/178, 37.1%) was the most common isolate, followed by Acinetobacter baumannii (36/178, 20.2%) , Klebsiella pneumoniae (24/178, 13.5%), Pseudomonas aeruginosa (20/178, 11.2%), Haemophilus influenzae (10/178,5.6%), Salmonella sp. (7/178, 3.9%), Enterobacter aerogenes (5/178, 2.8%), Stenotrophomonas maltophilia (5/178, 2.8%), Citrobacter freundii (3/178,1.7%), Proteus mirabilis (2/178,1.1%). Resistant isolates (53/178, 30.0%) were more common documented in GNB, mostly extended-spectrum beta-lactamase (ESBL) producing Escherichia coli (30/66, 45.5%) and Klebsiella pneumonia (6/24, 25%), and multi-drug resistant acinetobacter baumannii (36.1%). Susceptibility tests showed that the ESBLproducing strains were highly sensitive to carbapenems, β-lactamase inhibitor compound families, and certain cefalosporin (Cefepime and Ceftazidime) in vitro.
(the resistance rate <20%), whereas it was highly resistant to ampicillin and Gentamicin. Besides carbapenems and Cefoperazone/sulbactam, Acinetobacter baumannii was resistant to most antibiotics. Conclusions: GNB was predominant in Chinese hospitalized patients with SLE. The drug resistance of GNB has increased significantly. It was necessary to rational use of antibiotics in patients with SLE. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.1951 
